Home

Gary Sender

CIK 1659085 · Chief Financial Officer · last filed 2026-08-03

Gary Sender is a Chief Financial Officer who has filed 45 SEC Form 4 insider transactions across 5 companies since 2017. The most recent filing, for APMD, was dated Aug 3, 2026. Across all open-market trades the lifetime net is −$1.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $494.0K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$494.0K

Companies

5

Total Filings

45

Lifetime Open-Market Net

-$1.87M

Filer Profile

Reported Address
C/O SYNERGY PHARMACEUTICALS INC.
420 LEXINGTON AVE
NEW YORK, NY 10020
Related Filers
SYNERGY PHARMACEUTICALS, INC. — 1 joint filings, latest 2015-11-23
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
APMD Director — — — $0 1 2026-08-03
SDGR Director 25,388 $19.02 $482.9K -$1.91M 8 2026-06-23
HRMY Director — $41.52 — $0 7 2026-05-18
IBIO Director 9,191 $1.21 $11.1K $25.0K 5 2025-11-24
Nabriva Therapeutics plc (NBRV) Delisted Chief Financial Officer 819 $1.42 $1.2K $18.5K 23 2021-03-02

Recent Filings

45 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-03 APMD Mixed — $0 EDGAR
2026-06-23 SDGR Grant (A) +8,141 $0 EDGAR
2026-05-18 HRMY Grant (A) — $0 EDGAR
2025-11-24 IBIO Grant (A) — $0 EDGAR
2025-06-20 SDGR Grant (A) +5,997 $0 EDGAR
2025-05-16 HRMY Grant (A) — $0 EDGAR
2025-01-13 IBIO Buy (P) +9,191 $25.0K EDGAR
2024-11-25 IBIO Grant (A) — $0 EDGAR
2024-06-20 SDGR Grant (A) +5,000 $0 EDGAR
2024-05-31 HRMY Grant (A) — $0 EDGAR
Showing 1–10 of 45
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.